Responsible for Novartis participation in large-scale, global consortia to deliver high-impact scientific, clinical, and health policy outcomes for society. Driving full partnership value with clear governance and decision-making criteria, including strategic alignment across Global R&D, legal, data privacy and regulatory policy.

Set governance strategy to enable innovation while safeguarding data integrity, privacy, and ensuring regulatory and ethical compliance. Established legal framework and IP strategy for R&D data analytics platform, partnering with Legal and Data Science experts to enable novel business model. Implemented compliant platform governance including data quality practices and risk-based data access controls.

Transformed company-wide D&I strategy and approach, increasing equity and inclusivity in the workplace, inspiring individual and organizational accountability. Responsible for leading Global D&I function for all divisions and key countries. Delivered year-on-year progress toward gender balance in management, pay equity and transparency, and UN Standards for LGBTI equity. Generated company-wide dialogue and D&I awareness with global training and communications. Expanded D&I practices into core business operations, building trust with society and upholding Novartis’ position as industry leader in D&I.

Transformed the interface between Novartis Research (NIBR) and Global Drug Development (GDD), improving alignment and decision making to sustain a strong R&D pipeline. Increased cross-divisional collaboration and proportion of assets moving into full development pipeline. Established communication framework for enterprise-level transparency of Novartis Early Pipeline. Accelerated NIBR-to-GDD project transitions with a simplified governance process and biannual early pipeline assessments to guide functional and strategic planning.

Responsible for program management, strategic communications, Institute strategy and external alliances. Delivered high-impact drug discovery and technology projects by leading and developing a team of 4 Project Managers. Developed Institute-wide communication channels and initiatives; increased associate engagement and external media exposure. Streamlined portfolio visualization and publication approvals with custom data management systems. Supported Institute Director in strategic planning, organizing annual research reviews and Board of Director meetings.

Responsible for project team productivity across 7 disease areas and 2 technology platforms and for strategic alignment between GNF and NIBR leadership. Managed portfolio of ~100 small molecule and biologics projects; developed integrated FTE tracking system with Informatics and Finance. Ensured effective GNF-NIBR collaborations through positive stakeholder engagement and clear governance processes. Managed large, cross-functional project team through clinical PoC in addition to multiple preclinical teams.

Responsible for aligning Institute strategy with NIBR disease area strategies, managing growing research portfolio, driving project timelines and milestones, and optimizing drug discovery practices. Increased drug discovery efficiency by establishing Institute-wide portfolio governance and data management best practices. Streamlined communication and identified new collaboration opportunities by driving alignment among disease area and technology platform senior stakeholders.

Responsible for GNF-NIBR joint project teams and drug discovery process improvements. Managed early-stage project teams to deliver major preclinical milestones. Established productive collaborations with clear strategies across multiple sites. Optimized lead discovery data workflows and information management systems, including NIBR-wide Materials Transfer Database (interface design, user requirements analysis, beta testing, user guidelines and training).

Established Compound Management function including informatics, automation and workflow design. Developed and implemented custom data management system for compound registration, tracking, and ordering, which grew to include biologics, ADME assays, pharmacology and PK requests. Led Chemistry Operations during rapid build-up period; managed 7 scientists to successfully meet aggressive timelines for library plating and lead discovery follow-up.

Improved purification processes for biologics in a GLP / GMP environment. Developed large-scale adenovirus purification SOPs, HPLC methods, and glycosylation analysis protocols for efficacy and toxicology studies to support Phase II trials.